[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100478375":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":50,"locations":59,"responsibleParty":132,"collaborators":134,"id":144,"slug":145,"hasResults":146,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":146,"sex":151,"minAge":152,"maxAge":30,"enrollmentInfo":153,"targetDuration":30,"studyType":156,"phases":157,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":62,"whyStopped":30,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":172},{"fullName":5,"class":6},"Western Sydney Local Health District","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NAC","EXPERIMENTAL","1g N-Acetylcysteine capsules, taken orally twice a day.",[13],"Drug: NAC",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Coated Placebo capsules, taken orally twice a day",[19],"Drug: Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day",[9],[26],"N-Acetylcysteine",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day",[15],null,[32,36,39,42,45,48],{"name":33,"affiliation":34,"role":35},"Clement Loy","University of Sydney","PRINCIPAL_INVESTIGATOR",{"name":37,"affiliation":38,"role":35},"Yenni Lie","Calvary Health Care Bethlehem",{"name":40,"affiliation":41,"role":35},"Dennis Velakoulis","Melbourne Health",{"name":43,"affiliation":44,"role":35},"Carolyn Orr","Perron Institute",{"name":46,"affiliation":47,"role":35},"John O'Sullivan","The University of Queensland",{"name":49,"affiliation":47,"role":35},"Rob Adam",[51,55],{"name":33,"role":52,"phone":53,"phoneExt":30,"email":54},"CONTACT","001164 4 8890 3560","clement.loy@sydney.edu.au",{"name":56,"role":52,"phone":57,"phoneExt":30,"email":58},"Sarah Samperi","001164 2 8890 9146","sarah.samperi@health.nsw.gov.au",[60,78,93,106,119],{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Westmead Hospital","RECRUITING","Westmead","New South Wales","2145","Australia","AU",{"type":69,"coordinates":70},"Point",[71,72],150.98768,-33.80383,{"lat":72,"lon":71},[75,76,77],{"name":33,"role":52,"phone":30,"phoneExt":30,"email":54},{"name":56,"role":52,"phone":30,"phoneExt":30,"email":58},{"name":33,"role":35,"phone":30,"phoneExt":30,"email":30},{"facility":47,"status":79,"city":80,"state":81,"zip":82,"country":66,"countryCode":67,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"NOT_YET_RECRUITING","Herston","Queensland","4029",{"type":69,"coordinates":84},[85,86],153.01852,-27.44453,{"lat":86,"lon":85},[89,91,92],{"name":46,"role":52,"phone":30,"phoneExt":30,"email":90},"john.osullivan@uq.edu.au",{"name":46,"role":35,"phone":30,"phoneExt":30,"email":30},{"name":49,"role":35,"phone":30,"phoneExt":30,"email":30},{"facility":38,"status":79,"city":94,"state":95,"zip":96,"country":66,"countryCode":67,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Parkdale","Victoria","3195",{"type":69,"coordinates":98},[99,100],145.08128,-37.99187,{"lat":100,"lon":99},[103,105],{"name":37,"role":52,"phone":30,"phoneExt":30,"email":104},"Yenni.Lie@calvarycare.org.au",{"name":37,"role":35,"phone":30,"phoneExt":30,"email":30},{"facility":107,"status":79,"city":108,"state":95,"zip":109,"country":66,"countryCode":67,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"The Royal Melbourne Hospital","Parkville","3050",{"type":69,"coordinates":111},[112,113],144.95,-37.78333,{"lat":113,"lon":112},[116,118],{"name":40,"role":52,"phone":30,"phoneExt":30,"email":117},"Dennis.Velakoulis@mh.org.au",{"name":40,"role":35,"phone":30,"phoneExt":30,"email":30},{"facility":44,"status":79,"city":120,"state":121,"zip":122,"country":66,"countryCode":67,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Nedlands","Western Australia","6009",{"type":69,"coordinates":124},[125,126],115.8073,-31.98184,{"lat":126,"lon":125},[129,131],{"name":43,"role":52,"phone":30,"phoneExt":30,"email":130},"carolyn.orr@me.com",{"name":43,"role":35,"phone":30,"phoneExt":30,"email":30},{"type":35,"investigatorFullName":33,"investigatorTitle":133,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Director and Neurologist, Huntington Disease Service",[135,137,139,141,142],{"name":136,"class":6},"Deakin University",{"name":138,"class":6},"Monash University",{"name":140,"class":6},"Royal Perth Hospital",{"name":47,"class":6},{"name":143,"class":6},"University of Melbourne","100478375","phase-2-a-randomised-controlled-trial-of-n-acetyl-cysteine-nac-for-premanifest-huntingtin-gene-expansion-carriers-100478375",false,"NCT05509153","A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers","NAC-preHD","Inclusion Criteria:\n\n* Able to provide informed consent\n* Huntingtin gene expansion carrier with \\>= 39 CAG repeats\n* Absence of unequivocal motor signs of HD - that is, UHDRS\n* Diagnostic Confidence Level needs to be \\\u003C4 upon enrolment\n* Expected to develop clinical HD within 10 years of trial enrolment using the Langbehn formula\n* Availability of an informant for corroborative history\n* Negative serum pregnancy test for women of childbearing potential\n* If of childbearing potential, is able and agrees to remain abstinent or use adequate contraceptive methods\n* Ability to tolerate MRI scans\n* Ability to tolerate blood draws\n* Able to comply with all study protocol requirements, according to the investigators judgement\n* In the opinion of the investigator, medically, psychiatrically and neurologically stable at the time of enrolment\n\nExclusion Criteria:\n\n* Diagnosis of clinical HD\n* Known hypersensitivity to NAC\n* Pregnancy, breastfeeding or intention to do so prior to the end of the study\n* Exposure to any investigational drugs within 30 days of Baseline Visit\n* Use of supplemental NAC\n* Abnormalities in laboratory measurements, ECG or vital signs at screening, which precludes safe participation in the study\n* Current or history of substance abuse within one year of Baseline visit\n* Unstable psychiatric or acute medical illness including cancer, as determined by investigator\n* Current use of antipsychotic medications or Tetrabenazine\n* History of gene therapy, cell transplantation, or any experimental brain surgery\n* History of attempted suicide or suicidal ideation within 12 months prior to screening\n* Pre-existing structural brain lesion as assessed by a centrally read MRI scan during the screening period","ALL","18 Years",{"count":154,"type":155},160,"ESTIMATED","INTERVENTIONAL",[158],"PHASE2","NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.",[161],"Huntington Disease",[26],"2025-02-25",{"date":165,"type":166},"2025-02-28","ACTUAL",{"date":168,"type":166},"2024-06-01",{"date":170,"type":155},"2027-05-01",{"name":5,"class":6},5]